Isopropamide에 대한 Mechanism_Of_Action 정보 Not Available Trifluoperazine에 대한 Mechanism_Of_Action 정보 Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Pharmacology
Isopropamide에 대한 Pharmacology 정보 Isopropamide is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility. Trifluoperazine에 대한 Pharmacology 정보 Trifluoperazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Trifluoperazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.
Metabolism
Isopropamide에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Not Available Trifluoperazine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Xanthine dehydrogenase/oxidaseUDP-glucuronosyltransferase 1-4 (UGT1A4)
Protein Binding
Isopropamide에 대한 단백결합 정보 Not Available
Half-life
Isopropamide에 대한 반감기 정보 Not Available Trifluoperazine에 대한 반감기 정보 Not Available
Absorption
Trifluoperazine에 대한 Absorption 정보 Not Available
Pharmacokinetics
Isopropamide Iodide의 약물동력학자료
소실 : 주로 신배설된다.
Trifluoperazine의 약물동력학자료
대사 : 간대사 큼
반감기 : 장기 투여 : 24시간 이상
Biotransformation
Isopropamide에 대한 Biotransformation 정보 Not Available Trifluoperazine에 대한 Biotransformation 정보 Not Available
Toxicity
Isopropamide에 대한 Toxicity 정보 Symptoms of overdose include dryness of mouth, dysphagia, thirst, blurred vision, dilated pupils, photophobia, fever, rapid pulse and respiration, disorientation. Depression and circulatory collapse may result from severe overdosage. Trifluoperazine에 대한 Toxicity 정보 Symptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.
Drug Interactions
Isopropamide에 대한 Drug_Interactions 정보 Not Available Trifluoperazine에 대한 Drug_Interactions 정보 Not Available
Isopropamide에 대한 Description 정보 Isopropamide iodide is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility. Trifluoperazine에 대한 Description 정보 A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. [PubChem]
Dosage Form
Isopropamide에 대한 Dosage_Form 정보 Not Available Trifluoperazine에 대한 Dosage_Form 정보 Syrup OralTablet Oral
Drug Category
Isopropamide에 대한 Drug_Category 정보 Gastrointestinal Agents Trifluoperazine에 대한 Drug_Category 정보 AntiemeticsAntipsychotic AgentsAntipsychoticsDopamine AntagonistsPhenothiazines
Smiles String Canonical
Isopropamide에 대한 Smiles_String_canonical 정보 CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C Trifluoperazine에 대한 Smiles_String_canonical 정보 CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
Smiles String Isomeric
Isopropamide에 대한 Smiles_String_isomeric 정보 CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C Trifluoperazine에 대한 Smiles_String_isomeric 정보 CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
InChI Identifier
Isopropamide에 대한 InChI_Identifier 정보 InChI=1/C23H32N2O/c1-18(2)25(5,19(3)4)17-16-23(22(24)26,20-12-8-6-9-13-20)21-14-10-7-11-15-21/h6-15,18-19H,16-17H2,1-5H3,(H-,24,26)/p+1/fC23H33N2O/h24H2/q+1 Trifluoperazine에 대한 InChI_Identifier 정보 InChI=1/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3
Chemical IUPAC Name
Isopropamide에 대한 Chemical_IUPAC_Name 정보 [4-amino-4-oxo-3,3-di(phenyl)butyl]-methyl-di(propan-2-yl)azanium Trifluoperazine에 대한 Chemical_IUPAC_Name 정보 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine
Drug-Induced Toxicity Related Proteins
TRIFLUOPERAZINE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:D(2) dopamine receptor Drug:Trifluoperazine Toxicity:Antipsychotic response, tardive dyskinesia and acute akathisia. [바로가기]Replated Protein:D(3) dopamine receptor Drug:Trifluoperazine Toxicity:Antipsychotic response, tardive dyskinesia and acute akathisia. [바로가기]Replated Protein:D(4) dopamine receptor Drug:Trifluoperazine Toxicity:Antipsychotic response, tardive dyskinesia and acute akathisia. [바로가기]
사용자컨텐츠
항목
내용
최근정보수정일 2018-03-05
본 수정일 정보는 허가정보 이외의 기타정보 수정일을 의미하므로, 허가정보수정일은 본문에 표기된 날짜를 참조하시기 바랍니다.
알림
상세정보는 식품의약품안전처의 제품허가사항을 토대로 작성되었으며 요약정보는 상세정보 및 기타문헌을 기반으로 드럭인포에서 편집한 내용입니다. 제품허가사항의 목차와 다소 상이할 수 있습니다.
경고
드럭인포 의약학술정보는 식품의약품안전처의 제품허가사항, 학술문헌, 제약회사 제공정보 등을 근거로 작성된 참고 정보입니다.
정보의 정확성을 위해 노력하고 있으나 편집상의 오류, 허가사항 변경, 추가적인 학술연구 또는 임상연구 발표 등으로 인해 발생하는 문제에 대해 드럭인포는
책임을 지지 않습니다. 자세한 내용은 “책임의 한계 및 법적고지”를 참조해 주십시오.
반드시 제조·수입사, 판매사, 의사, 약사에게 최종적으로 확인하시기 바랍니다.
전화: 02-3486-1061 ㅣ 이메일: webmaster@druginfo.co.kr
The database contains the following fields: The generic name of each chemical For module A10 (liver enzyme composite module): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method) Number of endpoints at which each compound is marginally active (M) Number of endpoints at which each compound is active (A) For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method) Number of ADR reports for each compound, given as <4 or ≥4 Reporting Index value for each compound, except where no shipping units were available (NSU) Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period. TRIFLUOPERAZINE [GGT Increase] [Composite Activity] (Score) NA (Marginal) 0 (Active) 0
[Alkaline Phosphatase Increase] (Activity Score) NA (Number of Rpts) NA (Index value) NA
[SGOT Increase] (Activity Score) NA (Number of Rpts) NA (Index value) NA
[SGPT Increase] (Activity Score) NA (Number of Rpts) NA (Index value) NA
[LDH Increase] (Activity Score) NA (Number of Rpts) NA (Index value) NA
[GGT Increase] (Activity Score) NA (Number of Rpts) NA (Index value) NA
제목 없음2008년 8월 1일 약가화일상 8월달 신규등재 및 삭제되는 품목 포함한 병용연령 금기 품목리스트 기준 1. 현재 검색한 제품에 대한 병용금기 제품 존재여부 및 검색
현재 이제품에 대한 병용금기에 해당하는 청구코드별 제품내역 공지내용이 없습니다
2. 연령대금기 존재여부
현재 이제품에 대한 연령금기에 해당하는 청구코드별 공지내용이 없습니다
전문/일반
